PHILADELPHIA, March 31, 2016 /PRNewswire/ -- ControlRad announced that definitive results from an in vivo evaluation of its proprietary solution to considerably reduce patient and medical staff exposure to ionizing radiation during fluoroscopically guided interventional procedures (FGIP) have been published in the peer-reviewed journal Medical Physics.1
The published study demonstrated that use of the ControlRad technology reduced the radiation dose exposure to the patient and operators by approximately 75 percent, without interfering with the performance of the procedure. They also found that the radiation reducing technique produced a subjective enhancement of perceived visualization. Study authors included investigators from Columbia University, Mt. Sinai Hospital, CRF Skirball Center for Innovation, and the University of Pennsylvania.
"The risks of radiation exposure during interventional X-ray procedures to both patients and the medical staff are well documented," said Stephen Balter, Ph.D., Departments of Radiology and Medicine, Columbia University, and lead author of the study. "These results demonstrate a novel approach to dramatically reducing the radiation exposure by allowing the operator to optimize the X-ray beam using eye-tracking, without compromising either image quality or workflow."
Ad Statistics
Times Displayed: 112448
Times Visited: 6718 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
In the study, three types of paired interventional procedures were performed on swine using a mobile c-arm with the ControlRad technology. When the ControlRad technology was engaged, the subject and operator irradiation was decreased by approximately 75% as measured by multiple radiation measuring devices, including KAP (Kerma Area Product). Eye-tracking technology allowed the operator's gaze to dynamically define the region of interest throughout the procedure and optimize the X-ray beam for highest imaging resolution in the area being directly examined. Measurements of the amount of radiation delivered to both the subjects and the operators were taken with and without the ControlRad technology engaged.
"The impressive study results provide important validation of the clinical utility and potential benefits of our technology," said Guillaume Bailliard, President and CEO of ControlRad. "By allowing the operator seamless control of the X-ray beam, we are able to optimize it in the region of immediate clinical interest not only substantially reducing the radiation dose delivered to the patient but also dramatically reducing the lifetime radiation exposure to the medical staff."
